株式会社FerroptoCure
ActiveFerroptoCure specializes in ferroptosis research and the development of effective therapeutic drugs to treat cancer and other diseases.
What it does
"FerroptoCure is a medtech company specializing in ferroptosis research and the development of effective therapeutic drugs for treating cancer and other diseases. With a focus on scientific endeavors, FerroptoCure is likely involved in pharmaceuticals and biotechnology. The company's website features sections on research, pipelines, and news releases, indicating a primary focus on providing products and services related to healthcare and scientific technology. The presence of a copyright notice, "Copyright © FerroptoCure All Rights Reserved," in the website footer confirms the company's official name and ties it to the provided information. FerroptoCure is dedicated to advancing research, developing products, and providing services in the fields of healthcare and scientific technology."
Its site says now · captured 2026-08-23
FerroptoCure | Ferroptosisで病気を治す
Ferroptosisで病気を治す
Next to it in Healthcare and bio · ferroptosis cancer therapeutics
- Tradewind BioScienceY Combinator W18
Tradewind translates scientific insight into innovative ways of…
- ShasqiY Combinator W15
Targeting Cancer with Click Chemistry
- AutoPhagyGO Inc.Plug and Play
AutoPhagyGO develops autophagy solutions for the prevention and treatment of neurodegenerative diseases.
- Craif Inc.Plug and Play
Liquid biopsy startup company. Conducted cancer early diagnosis initiatives / リキッド・バイオプシーのスタートアップ企業。ガンの早期診断の取り組みを実施
- 株式会社メディネットPlug and Play
Cancer immuno-cell therapy is an advanced medical practice.
- OmnioxPlug and Play
a biotechnology company, commercializes technologies used in identifying and treating cancer, cardiovascular disease and trauma
- 株式会社PURMX TherapeuticsPlug and Play
PURMX is a pharmaceutical company that develops RNA nucleic acid medicine for therapeutic effects on intractable diseases.
- リバーセル株式会社Plug and Play
Rebirthel is a biotech company, focused on the Development and operationalization of cell-based cancer immunotherapies.